CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

被引：0

作者：

Exposito, M. J. Jimenez ^{[1
]}

Akce, M. ^{[2
]}

Montero Alvarez, J. L. ^{[3
]}

Assenat, E. ^{[4
]}

Balart, L. A. ^{[5
]}

Baron, A. D. ^{[6
]}

Decaens, T. ^{[7
]}

Heurgue-Berlot, A. ^{[8
]}

Martin, A. O. ^{[9
]}

Paik, S. W. ^{[10
]}

Poulart, V. ^{[11
]}

Sehbai, A. S. ^{[12
]}

Takemura, N. ^{[13
]}

Yoon, J-H. ^{[14
]}

机构：

[1] Bristol Myers Squibb, Clin Dev Oncol, Princeton, NJ USA

[2] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Hosp Univ Reina Sofia, Gastroenterol, Cordoba, Spain

[4] CHU Montpellier, Med Oncol, Hosp St Eloi, Montpellie, France

[5] Tulane Univ, Internal Med, Tulane Med Ctr, Hlth Sci Ctr, New Orleans, LA 70118 USA

[6] Calif Pacific, Med Ctr, San Francisco, CA USA

[7] CHU Grenoble Alpes, Clin Univ Hepatogastroenterol, Grenoble, France

[8] CHU Reims, Dept Hepatogastroenterol, Reims, France

[9] UAM, Digest Syst Serv, Hosp Univ La Paz, Madrid, Spain

[10] Sungkyunkwan Univ, Samsung Med Ctr, Gastroenterol, Seoul, South Korea

[11] Bristol Myers Squibb, Biostat, Braine Lalleud, Belgium

[12] Pinnacle Res Grp Llc, Hematol Oncol, Anniston, AL USA

[13] Tokyo Natl Ctr Global Hlth & Med, Gastroenterol Surg, Tokyo, Japan

[14] Seoul Natl Univ Hosp, Gastroenterol, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

783TiP

引用

页数：2

共 50 条

[41] Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial
Liu, Sai Lan
Mai, Hai-Qiang
Wen, Dongxiang
Yang, Jin-Hao
Guo, Shan-Shan
Liu, Li-Ting
Luo, Mei-Juan
Liang, YuJing
Sun, Xue-Song
Li, Xiao-Yun
Luo, Dong-Hua
Li, Ji-Bin
Wang, Pan
Guo, Ling
Mo, Hao-Yuan
Sun, Rui
Zhao, Chong
Xu, Rui-Hua
Tang, Lin-Quan
Chen, Qiu-Yan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
Weber, J.
Mandala, M.
Del Vecchio, M.
Gogas, H.
Arance, A. M.
Cowey, L. C.
Dalle, S.
Schenker, M.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Grob, J-J.
Butler, M.
Middleton, M. R.
Maio, M.
Atkinson, V.
Queirolo, P.
de Pril, V.
Qureshi, A.
Larkin, J.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2017, 28
[43] Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J. Motzer
Paul Russo
Viktor Grünwald
Yoshihiko Tomita
Bogdan Zurawski
Omi Parikh
Sebastiano Buti
Philippe Barthélémy
Jeffrey C. Goh
Dingwei Ye
Alejo Lingua
Jean-Baptiste Lattouf
Laurence Albigès
Saby George
Brian Shuch
Jeffrey Sosman
Michael Staehler
Sergio Vázquez Estévez
Burcin Simsek
Julia Spiridigliozzi
Aleksander Chudnovsky
Axel Bex
Targeted Oncology, 2023, 18 : 639 - 641
[44] Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Qin, Shukui
Chen, Zhendong
Fang, Weijia
Ren, Zhenggang
Xu, Ruocai
Ryoo, Baek-Yeol
Meng, Zhiqiang
Bai, Yuxian
Chen, Xiaoming
Liu, Xiufeng
Xiao, Juxiang
Ho, Gwo Fuang
Mao, Yimin
Wang, Xin
Ying, Jieer
Li, Jianfeng
Zhong, Wenyan
Zhou, Yu
Siegel, Abby B.
Hao, Chunyi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1434 - +
[45] Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Motzer, Robert J.
Russo, Paul
Gruenwald, Viktor
Tomita, Yoshihiko
Zurawski, Bogdan
Parikh, Omi
Buti, Sebastiano
Barthelemy, Philippe
Goh, Jeffrey C.
Ye, Dingwei
Lingua, Alejo
Lattouf, Jean-Baptiste
Albiges, Laurence
George, Saby
Shuch, Brian
Sosman, Jeffrey
Staehler, Michael
Vazquez Estevez, Sergio
Simsek, Burcin
Spiridigliozzi, Julia
Chudnovsky, Aleksander
Bex, Axel
TARGETED ONCOLOGY, 2023, 18 (05) : 639 - 641
[46] Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
Wu, Zhenjie
Wang, Linhui
Pandolfo, Savio D.
Autorino, Riccardo
EUROPEAN UROLOGY, 2023, 83 (03) : 297 - 298
[47] A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
Ciuleanu, T.
Bazin, I.
Lungulescu, D.
Miron, L.
Bondarenko, I.
Deptala, A.
Rodriguez-Torres, M.
Giantonio, B.
Fox, N. L.
Wissel, P.
Egger, J.
Ding, M.
Kalyani, R. N.
Humphreys, R.
Gribbin, M.
Sun, W.
ANNALS OF ONCOLOGY, 2016, 27 (04) : 680 - 687
[48] A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).
Goss, P. E.
Barrios, C. H.
Bell, R.
Finkelstein, D.
Iwata, H.
Martin, M.
Braun, A. H.
Dansey, R. D.
Coleman, R. E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[49] C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
Rischin, D.
Brungs, D.
Day, F.
Christie, H.
Patel, V. A.
Adams, G.
Jackson, J. E.
Schurmann, M. D. L. V.
Kirtbaya, D.
Shin, T. M.
Hart, C. D.
Stankevich, E.
Li, S.
Lowy, I.
Han, H.
Fury, M. G.
Porceddu, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E610 - E611
[50] Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
Choueiri, Toni K.
Tomczak, Piotr
Park, Se Hoon
Venugopal, Balaji
Ferguson, Tom
Chang, Yen-Hwa
Hajek, Jaroslav
Symeonides, Stefan N.
Lee, Jae-Lyun
Sarwar, Naveed
Thiery-Vuillemin, Antoine
Gross-Goupil, Marine
Mahave, Mauricio
Haas, Naomi B.
Sawrycki, Piotr
Zhang, Eric
Rogerio, Jaqueline Willemann
Imai, Kentaro
Quinn, David I.
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)

← 1 2 3 4 5 →